Total Arterial vs. Mixed Grafting in Left Coronary CABG
Launched by SECOND HOSPITAL OF JILIN UNIVERSITY · Jul 9, 2025
Trial Information
Current as of July 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways to perform heart bypass surgery for people with blocked arteries in the heart. The surgery, called coronary artery bypass grafting (CABG), helps improve blood flow by creating new paths around blocked arteries. This study compares using only artery grafts (from the chest and arm arteries) versus the usual method that uses a mix of artery and vein grafts (from the chest artery and leg veins) to see which approach works better after one year. The main goal is to check how well the grafts stay open, which is important for the heart to get enough blood. The study will also look at any complications after surgery and long-term heart health.
Adults who have multiple blocked heart arteries and are scheduled for planned bypass surgery involving at least three vessels may be eligible to join. People must be able to give informed consent and should not have had recent heart attacks, strokes, or other serious health problems that could affect surgery. Participants will be randomly assigned to one of the two grafting methods and will be followed for at least a year, including imaging tests to check the grafts. This study aims to help doctors choose the best type of grafts to improve outcomes for patients needing bypass surgery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years
- • 2. Diagnosed with multivessel coronary artery disease
- • 3. Indicated for elective coronary artery bypass grafting (CABG) involving ≥3 coronary vessels
- • 4. Right coronary artery stenosis \>75%
- • 5. Able and willing to provide written informed consent
- Exclusion Criteria:
- • 1. Scheduled for concurrent cardiac procedures (e.g., valve surgery, congenital heart disease repair, aortic dissection surgery, atrial fibrillation ablation)
- • 2. Severe stenosis of left or right subclavian artery
- • 3. Unsuitable saphenous veins (e.g., bilateral varicosities)
- • 4. Unsuitable radial artery as assessed preoperatively
- • 5. History of intracranial hemorrhage or ischemic stroke within the past 14 days
- • 6. Severe hepatic or renal insufficiency
- • 7. Acute myocardial infarction within 72 hours prior to surgery
- • 8. History of prior CABG or other cardiac surgery
About Second Hospital Of Jilin University
The Second Hospital of Jilin University is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital leverages its extensive expertise and state-of-the-art facilities to facilitate groundbreaking medical research across various disciplines. Committed to improving patient outcomes, the Second Hospital of Jilin University collaborates with multidisciplinary teams to ensure the highest standards of ethical practice and scientific rigor in all its clinical trials. Through these efforts, the institution aims to contribute significantly to the global medical community and enhance the overall quality of care provided to patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Changchun, Jilin, China
Patients applied
Trial Officials
Kexiang Liu
Principal Investigator
Department of Cardiovascular Surgery, The Second Hospital of Jilin University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported